Vous avez cherché: studiebehandling (Suédois - Anglais)

bästa totalt svar på studiebehandling
best overall response to study treatment [chemotherapy

i studie 1007 var mediantiden för studiebehandling
in study 1007, the median duration of study treatment was

en signifikant behandlingsinteraktion sågs med antihypertensiv studiebehandling.
there was significant treatment interaction by antihypertensive baseline therapy.

bästa totalt svar på studiebehandling [kemoterapi +/
best overall response to study treatment [chemotherapy

summering av biverkningar med en incidens på minst 10% per studiebehandling
summary of adverse events with an incidence rate of at least 10% by trial treatment

biverkningar per studiebehandling som rapporterades vid 1 år hos ≥ 1% av patienterna
adverse events reported at 1 year in ≥ 1% of patients, by study treatment

två av de randomiserade patienterna avslutade dock sitt studiedeltagande innan de fick någon studiebehandling.
however two of the randomized patients discontinued the study before receiving any study treatment

vanliga icke- hematologiska biverkningar per studiebehandling som rapporterades hos ≥ 10% av patienterna
common non-haematological adverse events reported in ≥ 10% of patients, by study treatment

följande tabell visar biverkningar per studiebehandling som rapporterades hos ≥ 10% av patienterna:
the following table displays adverse events which were reported in ≥ 10% of patients, by study treatment:

följande tabell visar biverkningar per studiebehandling och som rapporterades hos ≥ 10% av patienterna:
the following table displays adverse events which were reported in ≥ 10% of patients, by study treatment:

resultaten från primär- och uppföljningsanalysen presenteras utifrån avastinbehandling och studiebehandling i tabell 24 respektive tabell 25.
results from the primary analysis and the follow-up analysis are presented by avastin treatment and by trial treatment in table 24 and table 25, respectively.

den genomsnittliga tiden med studiebehandling var 118 veckor; 25 % av patienterna avbröt studiebehandlingen före vecka 48.
the median time on study therapy was 118 weeks; 25% of patients discontinued before week 48.

bästa totalt svar (cr + pr) på studiebehandling [kemoterapi +/- radioterapi] (%) (95% ci)
best overall response (cr + pr) to study treatment [chemotherapy +/- chemoradiotherapy] (%) (95% ci)

alla patienter fick studiebehandlingen som initial behandling för lokalt avancerad eller metastaserad icke- småcellig lungcancer och båda grupperna fick komplett tillägg av folsyra och vitamin b12.
all patients received study therapy as initial treatment for locally advanced or metastatic nsclc and patients in both treatment groups were fully supplemented with folic acid and vitamin b12.